Table 1. Baseline characteristics of all patients (n=147).
| Characteristics | Cases (n=147) | Percentage (%) |
|---|---|---|
| Age (years) | ||
| Mean | 53.9 | |
| Median | 55 | |
| Range | 47 to 63 | |
| Gender | ||
| Female | 53 | 36.1 |
| Male | 94 | 63.9 |
| Smoking history | ||
| Never smoking | 88 | 59.9 |
| Current or ever Smoking | 59 | 40.1 |
| Differentiation | ||
| Well | 6 | 4.0 |
| Moderate | 96 | 65.3 |
| Poor | 45 | 30.7 |
| pTNM stage | ||
| Ia | 11 | 7.5 |
| Ib | 28 | 19.0 |
| IIa | 8 | 5.4 |
| IIb | 14 | 9.6 |
| IIIa | 46 | 31.3 |
| IIIb | 7 | 4.8 |
| IV | 33 | 22.4 |
| pT status | ||
| T1 | 25 | 17.0 |
| T2 | 97 | 66.0 |
| T3+ T4 | 25 | 17.0 |
| pN status | ||
| N0+ N1 | 79 | 53.7 |
| N2+ N3 | 68 | 46.3 |
| pM status | ||
| M0 | 114 | 77.6 |
| M1 | 33 | 22.4 |
| Adjuvant chemotherapy | 40 | 45.5 |
| Yes | 101 | 68.7 |
| No | 46 | 31.3 |
| Serum CEA | ||
| Normal (≤5 ng/ml) | 71 | 48.3 |
| Elevated (>5ng/ml) | 76 | 51.7 |
| EGFR mutation status | ||
| Positive | 45 | 30.6 |
| Negative | 44 | 29.9 |
| Not performed | 58 | 39.5 |
| Anti-EGFR drug treatment | ||
| Yes | 70 | 47.6 |
| No | 77 | 52.4 |
| Plakoglobin expression | ||
| IRS 0-3 | 59 | 40.1 |
| IRS 4-12 | 88 | 59.9 |
Abbreviation: pTNM, pathologic tumor–node–metastasis; IRS: immunoreactivity score; CEA, carcinoembryonic antigen. EGFR: epidermal growth factor receptor.